about
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective ...
Read More
1.28
0.15
(13.27%)
1.6M
XNAS Volume
High volume+gain today
XNAS 21 Sep, 2026 5:30 PM (EDT)
Board Meeting
The next board meeting for MEI Pharma Inc is on 25 Sep 2026 for the purpose of Lite Strategy Inc Annual Report for 2026
See details
Not Eligible
Expensive Valuation
Technically Neutral
MEI Pharma Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..